In January 2025, leading German and international stakeholders from research and industry established the Radiopharmacy Cluster Dresden 鈥� nukliD. The cluster aims to position Saxony as a center of innovation and expertise in radiopharmacy, enhancing its international visibility in this cutting-edge field. Radiopharmacy is a specialized discipline focusing on the development, production, quality control, and distribution of radioactive drugs known as radiopharmaceuticals. These are used in theranostics, combining diagnostics and therapy within nuclear medicine. While diagnostic doses support imaging procedures, therapeutic doses play a crucial role in cancer treatment.
During the event, attendees gained valuable insights into nukliD and its objectives through presentations by distinguished speakers: Andr茅 Hofmann, CEO of leap:up GmbH; Jens Junker, CEO of ROTOP Pharmaka GmbH; and Andrew Varghese, President of ROTOP Pharma USA.
The presentations were followed by a multi-course dinner featuring an engaging discussion on recent innovations in radiopharmacy and emerging business opportunities across the Atlantic. The conversation was opened and moderated by Prof. Dr. Heribert Heckschen, Chapter Chair Saxony of AmCham Germany.
We would like to sincerely thank all participants for their contributions, especially Dr. Matthias Aldojohann and KPMG Law for supporting this special event in Dresden.
